{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=56",
    "query": {
      "intervention": "Branch II",
      "page": 56
    },
    "page_size": 10
  },
  "pagination": {
    "page": 56,
    "page_size": 10,
    "total_count": 4757,
    "total_pages": 476,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=57&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=55&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T06:07:54.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05913752",
      "title": "A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "CMND-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearmind Medicine Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2025-04-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05913752"
    },
    {
      "nct_id": "NCT02437071",
      "title": "Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Radiofrequency ablation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2015-04",
      "completion_date": "2024-09-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02437071"
    },
    {
      "nct_id": "NCT00027963",
      "title": "Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neurotoxicity",
        "Pain"
      ],
      "interventions": [
        {
          "name": "gabapentin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2002-02",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 22,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027963"
    },
    {
      "nct_id": "NCT06733363",
      "title": "A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Non-Muscle Invasive Bladder Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage 1 Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Behavioral Dietary Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Telephone- Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2026-01-13",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733363"
    },
    {
      "nct_id": "NCT07512284",
      "title": "Mindfulness Engaged Neurostimulation for Depression (MEND II)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depression",
        "Treatment Resistant Depression",
        "Major Depressive Disorder",
        "Depressive Disorder",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "Medi-TBS",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-05-01",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07512284"
    },
    {
      "nct_id": "NCT02311933",
      "title": "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Endoxifen Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2015-05-28",
      "completion_date": "2027-02-02",
      "has_results": true,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 559,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02311933"
    },
    {
      "nct_id": "NCT00410826",
      "title": "Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Squamous Cell Carcinoma of the Hypopharynx",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage IV Squamous Cell Carcinoma of the Hypopharynx",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-05-10",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 9,
      "location_summary": "Anchorage, Alaska • Miami, Florida • Albuquerque, New Mexico + 6 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410826"
    },
    {
      "nct_id": "NCT06831084",
      "title": "Acute Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer Patients With the Use of Silver-Plated Technology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Radiation Dermatitis Acute"
      ],
      "interventions": [
        {
          "name": "Silver plated technology (SPT) dressing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Parul Barry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2025-05-01",
      "completion_date": "2026-03-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06831084"
    },
    {
      "nct_id": "NCT07489885",
      "title": "A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "D-2570 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InventisBio Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 75,
      "start_date": "2026-06-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07489885"
    },
    {
      "nct_id": "NCT05139043",
      "title": "Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Brain Neoplasm",
        "Metastatic Malignant Neoplasm in the Brain",
        "Recurrent Malignant Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-04-09",
      "completion_date": "2025-09-03",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-25T06:07:54.770Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139043"
    }
  ]
}